Varenicline use in patients with mental illness: An update of the evidence

Expert Opinion on Drug Safety

Volumn 9, Issue 3, 2010, Pages 471-482

  Purvis, Tara L ^a   Nelson, Leigh Anne ^b   Mambourg, Scott E ^a  

^a VA Sierra Nevada Health Care System   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Mental illness; Psychiatry; Smoking; Tobacco cessation; Varenicline

Indexed keywords

AMFEBUTAMONE; CYTISINE; NICOTINE; NICOTINIC RECEPTOR ALPHA4BETA2; VARENICLINE;

ABNORMAL DREAMING; ABSTINENCE; ACUTE PSYCHOSIS; ALCOHOLISM; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BEHAVIOR CHANGE; BEHAVIOR DISORDER; BIPOLAR DISORDER; BLURRED VISION; CIGARETTE SMOKING; CLINICAL TRIAL; CONFUSION; DELIRIUM; DEPRESSION; DIZZINESS; DOPAMINERGIC SYSTEM; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG LABELING; DRUG MARKETING; EPIPHORA; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GROUP THERAPY; HALLUCINATION; HEADACHE; HUMAN; HYPERACTIVITY; HYPOMANIA; INSOMNIA; MAJOR DEPRESSION; MANIA; MENTAL CONCENTRATION; MENTAL DISEASE; MENTAL INSTABILITY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD DISORDER; NAUSEA; NICOTINE REPLACEMENT THERAPY; NIGHTMARE; PARANOIA; PATIENT CARE; PATIENT EDUCATION; PATIENT MONITORING; POSITIVE AND NEGATIVE SYNDROME SCALE; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PSYCHIATRIC DIAGNOSIS; PSYCHOSIS; RECOMMENDED DRUG DOSE; REINFORCEMENT; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SELF MEDICATION; SIDE EFFECT; SLEEP DISORDER; SMOKING CESSATION; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; TOBACCO DEPENDENCE; VENTRAL TEGMENTUM; VERTIGO; VISUAL HALLUCINATION; VIVID DREAM; VOLUNTARY REPORTING; WITHDRAWAL SYNDROME;

BENZAZEPINES; EVIDENCE-BASED MEDICINE; HUMANS; LIMBIC SYSTEM; MENTAL DISORDERS; MOOD DISORDERS; PATIENT EDUCATION AS TOPIC; QUINOXALINES; SMOKING; SMOKING CESSATION; SUICIDE; TREATMENT OUTCOME;

EID: 77951628241     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740331003657133     Document Type: Review

References (74)

1. Prevalence of current cigarette smoking among adults and changes in prevalence of current and some day smoking-United States, 1996-2001. JAMA 2003;289:2355-2356
2. Lasser K, Boyd JW, Woolhander S, et al. Smoking and mental illness: a population-based prevalence study. JAMA 2000;9:2606-2610
3. Stack NM. Smoking cessation: an overview of treatment options with a focus on varenicline. Pharmacotherapy 2007;27:1550-1557
4. Schroeder SA. A 51-year-old woman with bipolar disorder who wants to quit smoking. JAMA 2009;301:522-531
5. Lising-Enriquez K, George TP. Treatment of comorbid tobacco use in people with serious mental illness. J Psychiatry Neurosci 2009;34:E1-2
6. Mauer B. Morbidity and mortality in people with serious mental illness. In: Parks J, Svendsen D, Singer P, Foti ME, editors, Technical Report 13. National Association of State Mental Health Program Directors Council, Alexandria, VA; 2006
7. Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 Update Practice Guidelines. Public Health Service, Rockville, MD; 2008
8. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. JAMA 2006;296:47-55
9. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. JAMA 2006;296:56-63
10. Oncken CO, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006;166:1571-1577
11. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist. Arch Intern Med 2006;166:1561-1568
12. Tsai ST, Cho HJ, Cheng HS, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007;29:1027-1039
13. Nakamura M, Oshima A, Fujimoto Y, et al. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007;29:1040-1056
14. Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation. JAMA 2006:296:64-71
15. Aubin H-J, Bobak A, Britton JE, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomized open-label trial. Thorax 2008;63:717-724
16. Stapleton JA, Watson L, Spirling LI, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2007;103:146-154
17. Product information. Chantix (varenicline). Pfizer, New York, NY; 2009
18. FDA requires new boxed warnings for the smoking cessation drugs chantix and zyban. FDA Public Health Advisory. Washington, DC: FDA/Center for Drug Evaluation and Research, 2009. Available from: http://www.fda.gov/Drugs/ DrugSafety/PublicHealthAdvisories/ucm169988.htm. [Last accessed 28 October 2009]
19. Medicines and Healthcare Products Regulatory Agency. Drug analysis print-varenicline [online]. Available from: http://www.mhra.gov.uk/ Safetyinformation/Reportingsafetyproblems/Medicines/ Reportingsuspectedadversedrugreactions/Druganalysisprints/index.htm. [Last accessed 14 October 2009]
20. Department of Health, Education, and Welfare. The health consequences of smoking: nicotine addiction: a report of the Surgeon General: 1988. Government Printing Office, Washington DC; 1988
21. Hays JT, Ebbert JO. Varencline for tobacco dependence. N Engl J Med 2008;359:2018-2024
22. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 2000;393:295-314
23. Maskos U, Molles BE, Pons S, et al. Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature 2005;436:103-107
24. Picciotto MR, Zoli M, Rimondini R, et al. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 1998;391:173-177
25. Tapper AR, McKinney SL, Nashmi R, et al. Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science 2004;306:1029-1032
26. Anthenelli RM. Recent advances in the treatment of tobacco dependence. Clin Neurosci Res 2005;5:175-183
27. Papke RL, Heinemann SF. Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta2 subunit. Mol Pharm 1994;45:142-149
28. Slater YE, Houlihan LM, Maskell PD, et al. Halogenated cytisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes. Neuropharmacology 2003;44:503-515
29. Etter JF. Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Int Med 2006;166:1-7
30. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist of smoking cessation. J Med Chem 2005;48:3474-3477
31. Jimenez-Ruiz C, Berlin I, Hering T. Varenicline A novel pharmacotherapy for smoking cessation. Drugs 2009;69:1319-1338
32. Benowitz NL. Neurobiology of nicotine addiction: implications for smoking cessation treatment. Am J Med 2008;121:S3-10
33. Cahill K, Stead L, Lancaster T. A preliminary benefit-risk assessment of varenicline in smoking cessation. Drug Saf 2009;32:119-135
34. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Text rev. American Psychiatric Association, Washington DC; 2000
35. Moore TJ. Strong safety signal seen for new varenicline risks. The institute for safe medication practices. 22 May 2008. Available from: http://www.ismp.org/docs/vareniclinestudy.asp. [Last accessed 10 October 2009]
36. Kessler RC, Berglund PA, Borges G, et al. Smoking and suicidal behaviors in the National Comorbidity Survey-Replication. J Nerv Ment Dis 2007;195:369-377
37. Kasliwal R, Wilton LV, Shakir SAW. Safety and drug utilization profile of varenicline as used in general practice in England. Drug Saf 2009;32:499-507
38. Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med 2007;167:1752-1759
39. Laine P, Marttila J, Lindeman S. Hallucinations in the context of varenicline withdrawal. Am J Psychiatry 2009;166:619-620
40. Raidoo M, Kutscher EC. Visual hallucinations associated with varenicline: a case report. J Med Case Rep 2009;8:7560
41. Kutscher EC, Stanley M, Oehlke K. Chantix®-induced mental status changes in a young healthy female. S D Med 2009;62:193-195
42. Alhatem F, Black JE. Varenicline-induced mania in a bipolar patient. Clin Neuropharmacol 2009;32:117-118
43. DiPaula BA, Thomas MD. Worsening psychosis induced by varenicline in a hospitalized psychiatric patient. Pharmacotherapy 2009;29:852-857
44. Kintz P, Evans J, Villain, et al. Smoking cessation with varenicline: a suicidal fatality. J Anal Toxicol 2009;33:118-120
45. Lyon GJ. Possible varenicline-induced paranoia and irritability in a patient with major depressive disorder, borderline personality disorder, and methamphetamine abuse in remission. J Clin Psychopharmacol 2008;28:720-721
46. Spirling LI, Stapleton JA, Sutherland G. Suicidal ideation and varenicline: a possible case of mistaken adverse drug reaction? J Clin Psychiatry 2008;69:1834-1835
47. Pirmoradi P, Roshan S, Nadeem SS. Neuropsychiatric disturbance after initiation of varenicline in a patient with a history of alcohol abuse and major depression. Am J Health Syst Pharm 2008;65:1624-1626
48. Popkin MK. Exacerbation of recurrent depression as a result of treatment with varenicline. Am J Psychiatry 2008;165:774
49. Pumariega AJ, Nelson R, Rotenberg L. Varenicline-inducted mixed mood and psychotic episode in a patient with a past history of depression. CNS Spectr 2008;13:511-514
50. Morstad AE, Kutscher EC, Kennedy WK, et al. Hypomania with agitation associated with varenicline use in bipolar II disorder. Ann Pharmacother 2008;42:288-289
51. Kohen I, Kremen N. Varenicline induced manic episode in a patient with bipolar disorder. Am J Psychiatry 2007;164:1269-1270
52. Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry 2007:164;1269
53. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245 (Pubitemid 12149145)
54. Purvis TL, Mambourg SE, Balvanz TM, et al. Safety and effectiveness of varenicline in a veteran population with a high prevalence of mental illness. Ann Pharmacother 2009;43:862-867
55. Evins AE. Varenicline treatment for smokers with schizophrenia: a case series. J Clin Psychiatry 2008;69:1016
56. Fatemi SH. Varenicline efficacy and tolerability in a subject with schizophrenia. Schizophr Res 2008;103:328-329
57. Alder LE, Hoffer LD, Wiser A, et al. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 1993;150:1856-1861
58. Alder LE, Olincy A, Waldo M, et al. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 1998;24:189-202
59. Freedman R, Coon H, Myles-Worsley M, et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci 1997;94:587-592
60. Mihakak K, Carroll F, Leutje C. Varenicline is a parietal agonist at [alpha]4 [beta]2 and full agonist at [alpha]7 neuronal nicotinic receptors. Mol Pharmacol 2006;70:801-805
61. Smith RC, Lindenmayer JP, Davis JM, et al. Cognitive and antismoking effects of varenilcine in patients with schizophrenia or schizoaffective disorder. Schizophr Res 2009;110:149-155
62. Anghelescu I. Successful smoking cessation and improvement of negative symptoms with varenicline in a stable schizophrenia patient. J Neuropsychiatry Clin Neurosci 2009;21:102
63. Mineur YA, Somenzi O, Picciotto M. Cystine, a partial agonist of high affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice. Neuropharmacology 2007;52:1256-1262
64. Shytle RD, Silver AA, Lukas RJ, et al. Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry 2002;7:525-535
65. Philip NS, Carpenter LL, Tyrka AR, et al. Varenicline augmentation in depressed smokers: an 8-week, open-label study. J Clin Psychiatry 2009;70:1026-1031
66. MClure JB, Swan GE, Jack L, et al. Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. J Gen Intern Med 2009;24:563-569
67. Ochoa E. Varenicline reduced smoking behavior in a mentally ill person. J Psychopharmacol 2009;23:340-341
68. Patterson F, Jepson C, Strasser AA, et al. Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry 2009;65:144-149
69. Cocores JA, Gold MS. Varenicline and adult ADHD. J Neuropsychiatry Clin Neurosci 2008;20:494-495
70. Gunnell D, Wise L, Davies C, et al. Varenicline and suicidal behavior: a cohort study based on data from the General Practice Research Database. BMJ 2009;339:b3805
71. US Register of Clinical Trials [online]. Available from: http://www.clinicaltrials. gov/ct2/results?term=varenicline. [Last accessed 31 October 2009]
72. Benowitz NL. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther 2008;83:531-541
73. Ziedonis DM, Kosten TR, Glazer WM, et al. Nicotine dependence and schizophrenia. Hosp Community Psychiatry 1994;45:204-206
74. Fowler JS, Volkow ND, Wang GJ, et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996;379:733-736